{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:23:51Z","timestamp":1791062631179,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T00:00:00Z","timestamp":1420502400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1038\/nrrheum.2014.222","type":"journal-article","created":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T13:07:49Z","timestamp":1420549669000},"page":"72-74","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Advances in cohort enrichment shape future of trial design"],"prefix":"10.1038","volume":"11","author":[{"given":"Yannick","family":"Allanore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,6]]},"reference":[{"key":"BFnrrheum2014222_CR1","doi-asserted-by":"publisher","unstructured":"Cobo-Ib\u00e1\u00f1ez, T.  et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin. Arthritis Rheum. \n                    http:\/\/dx.doi.org\/10.1016\/j.semarthrit.2014.04.002\n                    \n                  .","DOI":"10.1016\/j.semarthrit.2014.04.002"},{"key":"BFnrrheum2014222_CR2","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","volume":"6","author":"RK Burt","year":"2011","unstructured":"Burt, R. K.  et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 6, 498\u2013506 (2011).","journal-title":"Lancet"},{"key":"BFnrrheum2014222_CR3","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"25","author":"JM van Laar","year":"2014","unstructured":"van Laar, J. M.  et al. EBMT\/EULAR Scleroderma Study Group. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 25, 2490\u20132498 (2014).","journal-title":"JAMA"},{"key":"BFnrrheum2014222_CR4","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/art.38390","volume":"66","author":"SI Nihtyanova","year":"2014","unstructured":"Nihtyanova, S. I.  et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheum. 66, 1625\u20131635 (2014).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014222_CR5","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","volume":"51","author":"M Elhai","year":"2012","unstructured":"Elhai, M., Meune, C., Avouac, J., Kahan, A. & Allanore, Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 51, 1017\u20131026 (2012).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014222_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/BOR.0000000000000027","volume":"26","author":"M Nikpour","year":"2014","unstructured":"Nikpour, M. & Baron, M. Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. Curr. Opin. Rheumatol. 26, 131\u2013137 (2014).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum2014222_CR7","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO;2-7","volume":"42","author":"PJ Clements","year":"1999","unstructured":"Clements, P. J.  et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum. 42, 1194\u20131203 (1999).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014222_CR8","doi-asserted-by":"publisher","unstructured":"Nagaraja, V., Denton, C. P. & Khanna, D. Old medications and new targeted therapies in systemic sclerosis. Rheumatology (Oxford) \n                    http:\/\/dx.doi.org\/10.1093\/rheumatology\/keu285\n                    \n                  .","DOI":"10.1093\/rheumatology\/keu285"},{"key":"BFnrrheum2014222_CR9","doi-asserted-by":"publisher","unstructured":"Maurer, B.  et al. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann. Rheum. Dis. \n                    http:\/\/dx.doi.org\/10.1136\/annrheumdis-2014-205226\n                    \n                  .","DOI":"10.1136\/annrheumdis-2014-205226"},{"key":"BFnrrheum2014222_CR10","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1002\/art.34427","volume":"64","author":"PA Merkel","year":"2012","unstructured":"Merkel, P. A.  et al. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 64, 3420\u20133429 (2012).","journal-title":"Arthritis Rheum."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2014.222.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2014.222","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2014.222.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:35:26Z","timestamp":1684470926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2014.222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,6]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["BFnrrheum2014222"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2014.222","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,6]]},"assertion":[{"value":"6 January 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.A. declares that he has received honoraria or research grants from Actelion, Bayer, Inventiva, Medac, Pfizer, Roche\/Genentech, Sanofi and Servier. O.D. declares that he has consulted for, or has received research funding from, 4D Science, Actelion, Active Biotec, Bayer-Schering, Biogen, Biovitrium, BMS, Boehringer Ingelheim Pharma, EpiPharm, Ergonex, GSK, Inventiva, Medac, Novartis, Pfizer, Roche\/Genentech, Sanofi\/Genzyme, Serodapharm, Sinoxa and United BioSource Corporation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}